drugset / Trial / NCT02506686

Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment

NCT02506686

Phase 4 Completed 82 enrolled Huashan Hospital
NaSingle-groupOpen-labelTreatment

Summary

A prospective, open-label study investigated the pharmacokinetic profile of meropenem in patients with post-neurosurgical central nervous system (CNS) infection, especially its BBB penetration into cerebrospinal fluid (CSF).

Timeline

Start
2008-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Meropenem Small molecule 1 g Intravenous
Subject Meropenem Small molecule 2 g Intravenous